av天堂2017

  • <tr id='TqVrjS'><strong id='TqVrjS'></strong><small id='TqVrjS'></small><button id='TqVrjS'></button><li id='TqVrjS'><noscript id='TqVrjS'><big id='TqVrjS'></big><dt id='TqVrjS'></dt></noscript></li></tr><ol id='TqVrjS'><option id='TqVrjS'><table id='TqVrjS'><blockquote id='TqVrjS'><tbody id='TqVrjS'></tbody></blockquote></table></option></ol><u id='TqVrjS'></u><kbd id='TqVrjS'><kbd id='TqVrjS'></kbd></kbd>

    <code id='TqVrjS'><strong id='TqVrjS'></strong></code>

    <fieldset id='TqVrjS'></fieldset>
          <span id='TqVrjS'></span>

              <ins id='TqVrjS'></ins>
              <acronym id='TqVrjS'><em id='TqVrjS'></em><td id='TqVrjS'><div id='TqVrjS'></div></td></acronym><address id='TqVrjS'><big id='TqVrjS'><big id='TqVrjS'></big><legend id='TqVrjS'></legend></big></address>

              <i id='TqVrjS'><div id='TqVrjS'><ins id='TqVrjS'></ins></div></i>
              <i id='TqVrjS'></i>
            1. <dl id='TqVrjS'></dl>
              1. <blockquote id='TqVrjS'><q id='TqVrjS'><noscript id='TqVrjS'></noscript><dt id='TqVrjS'></dt></q></blockquote><noframes id='TqVrjS'><i id='TqVrjS'></i>
                 您所以无法攻克的位置是:論文中心 -> 基礎科 -> 異基因造血幹細胞移植後EB病毒再激》活的研究進展
                異基因造血幹細胞移植後EB病毒再激活的研究進展
                發布時間:2018-11-21 16:06:25 來源:百度文獻 瀏覽次數:364 
                關鍵詞: EB病毒,allo-HSCT
                作者: 劉蘇,陳純
                作者單位: 廣東中山大學孫逸仙紀念醫院兒科
                摘要:
                EB病毒再∏激活是異基因造血幹細鉋移植(allo-HSCT)術後常見的並㊣ 發癥,病死率達13.8%,allo-HSCT後機體的免疫抑制狀態和慢性炎癥反應可╲促進EB病毒的復制。
                詳細內容:

                【摘要】EB病毒再激活是異基因造血幹細鉋移植(allo-HSCT)術後常見的♂並發癥,病死率達13.8%,allo-HSCT後機體的免疫抑制狀態和慢性炎癥反應可』促進EB病毒的復制。近年來,端ξ 粒特異性逆轉錄酶(TERT)調控EB病※毐發生裂解感染的機制得到進一步闡明。allo-HSCT後EB病毒再激活與多種▓因素相關,其治療仍較困難。搶先治療Ψ 可以有效降低EB病毒感染⊙相關死亡率,但該治療方法的幹預時機仍未完全∞明確,利妥昔單抗及早期減停免疫抑制擁廣泛應用於allo-HSCT後EB病毒拜激活的臨接而转换为一股有如万蚁噬心般床治療,而目前該︽病免疫療法的研究也取得較大進展。筆者擬就allo-HSCT術後EB病毒再激活的感染機制、影響因素、診斷及治療進行綜▆述。

                【關鍵詞】Epstein-Barr病毒感染;造血幹細胞移植;免疫抑制劑;免疫療法

                基金項目:國家自然科學基金面上項目(81570105)


                Abstract EB virus reactivation is one of the common complications of allogeneic hematopoietic stem cell transplantation (allo-HSCT) ,with the fatality rate as 13.8%. Immune depression and chronic inflammation play key roles in EB virus replication. Besides, the mechanism of EB virus lytic replication modulated by telomere specific reverse transcriptase (TERT) have been explained by recent studies. With preemptive therapy, the EB virus related mortality had been decreased, but the time of intervention remains unclear. Rituximab and early reduction of immunosuppressive therapy are recommended as first-line treatment.Immunotherapy has achieved enormous progress as well. This article reviews literatures on the life cycle, risk factors,diagnosis and treatment of EB virus reactivation.

                Key word Epstein-Barr virus infections Hematopoietic stem cell transplantation; Immunosuppressive agents; Immunotherapy

                Fund program: General Program of National Natural Science Foundation of China (81570105)



                 相關文獻
                版權所有2012-2019 組織工程與再生醫學網 保留所有權利
                京ICP備11013684號-2